Abingworth LLP - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 187 filers reported holding CRISPR THERAPEUTICS AG in Q3 2018. The put-call ratio across all filers is 2.47 and the average weighting 0.6%.

Quarter-by-quarter ownership
Abingworth LLP ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q3 2020$21,684,000
-43.0%
259,599
-50.0%
4.64%
-56.4%
Q2 2020$38,062,000
+73.4%
519,1980.0%10.64%
-27.0%
Q1 2020$21,952,000
-30.6%
519,1980.0%14.58%
-4.6%
Q4 2019$31,619,000
+22.8%
519,198
-17.4%
15.28%
-6.1%
Q3 2019$25,745,000
-53.2%
628,398
-46.3%
16.28%
-22.9%
Q2 2019$55,050,000
+31.6%
1,171,2680.0%21.11%
-43.6%
Q1 2019$41,826,000
+25.0%
1,171,2680.0%37.43%
+23.1%
Q4 2018$33,463,000
-39.0%
1,171,268
-5.3%
30.40%
-6.8%
Q3 2018$54,858,000
-24.5%
1,237,2020.0%32.62%
-21.5%
Q2 2018$72,698,000
-15.7%
1,237,202
-34.4%
41.53%
-22.5%
Q1 2018$86,207,000
+88.2%
1,887,202
-3.3%
53.59%
+61.5%
Q4 2017$45,798,000
+30.3%
1,951,359
-1.0%
33.18%
+36.4%
Q3 2017$35,139,000
-9.8%
1,971,907
-19.3%
24.33%
-21.6%
Q2 2017$38,970,000
-31.2%
2,444,809
-6.0%
31.01%
-26.5%
Q1 2017$56,641,000
+8.8%
2,601,8140.0%42.20%
-3.0%
Q4 2016$52,036,0002,601,81443.50%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q3 2018
NameSharesValueWeighting ↓
Versant Venture Management, LLC 508,558$82,330,00027.28%
Valiant Capital Management, L.P. 307,700$49,814,0003.74%
NEA Management Company, LLC 1,590,002$257,405,0003.35%
NIA IMPACT ADVISORS, LLC 39,891$6,458,0003.15%
Ikarian Capital, LLC 200,000$32,379,0002.62%
Soleus Capital Management, L.P. 103,114$16,693,0002.57%
HIMENSION CAPITAL (SINGAPORE) PTE. LTD. 157,334$25,471,0002.47%
Capital Impact Advisors, LLC 45,440$7,356,0002.37%
ARK Investment Management 7,776,119$1,258,876,0002.34%
Sassicaia Capital Advisers LLC 13,513$2,188,0002.28%
View complete list of CRISPR THERAPEUTICS AG shareholders